Venture Life (VLG) · 2026-09-29
Venture Life reported 16.0% pro forma revenue growth in its 17-month results, but adjusted EBITDA margin fell to 15.7% amid transformation investment and customer-order volatility. The Board remains highly confident of meeting FY27 market expectations.
Venture Life Group plc (VLG) · 2026-08-20
Venture Life Group is seeking to repurchase up to 3,871,288 Ordinary Shares by 29 September 2026, funded from existing cash resources.
Venture Life Group PLC (VLG) · 2026-07-13
Venture Life Group transferred 257,500 ordinary shares out of treasury on 10 July 2026 to settle employee options. Following the transfer, shares in issue will be 128,860,145 and treasury shares 7,535,904.
Venture Life Group (VLG) · 2026-06-30
Venture Life said revenue and adjusted EBITDA for the seventeen months to 31 May 2026 are in line with management expectations. Group revenue rose 28.9% to £14.7m in the five months to 31 May 2026.
Venture Life Group PLC (VLG) · 2026-06-04
Venture Life said Mr McGreevy bought 88,273 ordinary shares on 3 June 2026 at a volume-weighted average price of 62.3p. He now holds 1,052,098 shares, about 0.82% of the company.
Venture Life Group plc (VLG) · 2026-06-03
Venture Life Group acquired FemiClear and CUROXEN from OrganiCare Nature's Sciences for up to $28.0m. The brands generated combined net revenues of around $12.1m over the twelve months to 31 March 2026.